SCHEMBL5539624

SCHEMBL5539624

[CH2]c1ccc(Oc2c(F)cccc2F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 4/20 0.40
LPAR5 Q9H1C0 4/20 0.40
SLC6A2 P23975 5/20 0.39
HTR1A P08908 4/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 2/20 0.39
DHODH Q02127 1/20 0.38
GCK P35557 2/20 0.35
POLB P06746 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33
PARP10 Q53GL7 1/20 0.33
AR P10275 1/20 0.33
TNK2 Q07912 2/20 0.32
EPAS1 Q99814 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA13 Q8N1Q1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515736 0.78 ALDH1A1 (0.54) LPAR1LPAR5POLBHSP90AA1MAPT
SCHEMBL21486338 0.78 TEAD4 (0.45) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL13861391 0.78 LPAR1 (0.40) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL17423587 0.78 MAPT (0.45) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL1129355 0.78 MAPT (0.45) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL5546635 0.77 HSD17B10 (0.47) POLBHSP90AA1MAPTCA12CA1
SCHEMBL2089927 0.77 PARP10 (0.56) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL16415975 0.75 SLC6A2 (0.45) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL1222234 0.74 SLC6A2 (0.39) LPAR1LPAR5SLC6A2HTR1ASLC6A4
SCHEMBL5544007 0.74 MAPT (0.41) LPAR1LPAR5POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LPAR1 2085/4885LPAR5 3648/4885SLC6A2 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.